Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines

American Journal of Cancer Research

Volumn 6, Issue 12, 2016, Pages 2831-2845

  Gumbarewicz, Ewelina ^a   Luszczki, Jarogniew J ^a   Wawruszak, Anna ^a   Dmoszynska Graniczka, Magdalena ^a   Grabarska, Aneta J ^a   Jarzab, Agata M ^a   Polberg, Krzysztof ^b   Stepulak, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MSW Hospital   (Poland)

Author keywords

Cisplatin (CDDP); Histone deacetylase inhibitors (HDIs); Isobolographic analysis; Lung cancer; Suberoylanilide hydroxamid acid (SAHA); Valproic acid (VPA)

Indexed keywords

CISPLATIN; HISTONE DEACETYLASE INHIBITOR; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; SQUAMOUS CELL LUNG CARCINOMA; STATISTICAL ANALYSIS;

EID: 85009919911     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Malvezzi M, Arfe A, Bertuccio P, Levi F, La Vecchia C and Negri E. European cancer mortality predictions for the year 2011. Ann Oncol 2011; 22: 947-956.
2. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
4. Cohen SM and Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001; 67: 93-130.
5. Takahara PM, Rosenzweig AC, Frederick CA and Lippard SJ. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 1995; 377: 649-652.
6. Viet CT, Dang D, Achdjian S, Ye Y, Katz SG and Schmidt BL. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. PLoS One 2014; 9: e112880.
7. Zhang Q, Cai XW, Zhu ZF, Yu W, Liu Q, Feng W, Xue MC and Fu XL. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated adva-nced nonsquamous non-small cell lung cancer. Anticancer Drugs 2015; 26: 456-463.
8. Petta V, Gkiozos I, Strimpakos A and Syrigos K. Histones and lung cancer: are the histone deacetylases a promising therapeutic target? Cancer Chemother Pharmacol 2013; 72: 935-952.
9. Blaheta RA and Cinatl J Jr. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002; 22: 492-511.
10. Noro R, Miyanaga A, Shimokawa T, Kuribayashi H, Mizutani H, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A and Gemma A. The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application. J Nippon Med Sch 2009; 76: 44-46.
11. Gurvich N, Tsygankova OM, Meinkoth JL and Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004; 64: 1079-1086.
12. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA and Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
13. Roth SY, Denu JM and Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
14. Wolffe AP and Hayes JJ. Chromatin disruption and modification. Nucleic Acids Res 1999; 27: 711-720.
15. Iizuka M and Smith MM. Functional consequences of histone modifications. Curr Opin Genet Dev 2003; 13: 154-160.
16. Dodurga Y, Gundogdu G, Tekin V, Koc T, Satiroglu-Tufan NL, Bagci G and Kucukatay V. Val-proic acid inhibits the proliferation of SHSY5Y neuroblastoma cancer cells by downregulating URG4/URGCP and CCND1 gene expression. Mol Biol Rep 2014; 41: 4595-4599.
17. Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M and Rodriguez R. Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J Biomed Biotechnol 2012; 2012: 180363.
18. Gan CP, Hamid S, Hor SY, Zain RB, Ismail SM, Wan Mustafa WM, Teo SH, Saunders N and Cheong SC. Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck 2012; 34: 344-353.
19. Shah RD, Jagtap JC, Mruthyunjaya S, Shelke GV, Pujari R, Das G and Shastry P. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition. J Cell Biochem 2013; 114: 854-863.
20. Jiang W, Zheng Y, Huang Z, Wang M, Zhang Y, Wang Z, Jin X and Xia Q. Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness. Int Urol Nephrol 2014; 46: 941-946.
21. Seo SK, Jin HO, Lee HC, Woo SH, Kim ES, Yoo DH, Lee SJ, An S, Rhee CH, Hong SI, Choe TB and Park IC. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol Pharmacol 2008; 73: 1005-1012.
22. Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW and Koeffler HP. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 2006; 15: 187-191.
23. Li CT, Hsiao YM, Wu TC, Lin YW, Yeh KT and Ko JL. Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells. J Cell Biochem 2011; 112: 3044-3053.
24. Han S, Fukazawa T, Yamatsuji T, Matsuoka J, Miyachi H, Maeda Y, Durbin M and Naomoto Y. Anti-tumor effect in human lung cancer by a combination treatment of novel histone dea-cetylase inhibitors: SL142 or SL325 and retinoic acids. PLoS One 2010; 5: e13834.
25. Knutson AK, Welsh J, Taylor T, Roy S, Wang WL and Tenniswood M. Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells. Oncol Rep 2012; 27: 849-853.
26. Hutt DM, Roth DM, Vignaud H, Cullin C and Bouchecareilh M. The histone deacetylase inhibitor, vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition. PLoS One 2014; 9: e106224.
27. Yang H, Lan P, Hou Z, Guan Y, Zhang J, Xu W, Tian Z and Zhang C. Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma. Br J Cancer 2015; 112: 112-121.
28. Chiao MT, Cheng WY, Yang YC, Shen CC and Ko JL. Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. Autophagy 2013; 9: 1509-1526.
29. Gueugnon F, Cartron PF, Charrier C, Bertrand P, Fonteneau JF, Gregoire M and Blanquart C. New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells. Oncotarget 2014; 5: 4504-4515.
30. Wawruszak A, Luszczki JJ, Grabarska A, Gumbarewicz E, Dmoszynska-Graniczka M, Polberg K and Stepulak A. Assessment of interactions between cisplatin and two histone deacetylase inhibitors in MCF7, T47D and MDA-MB-231 human breast cancer cell lines-an isobolographic analysis. PLoS One 2015; 10: e0143013.
31. Litchfield JT Jr and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949; 96: 99-113.
32. Luszczki JJ. Isobolographic analysis of inter-action between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn Schmiedebergs Arch Pharma-col 2007; 375: 105-114.
33. Luszczki JJ and Czuczwar SJ. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Naunyn Schmiedebergs Arch Pharmacol 2006; 374: 51-64.
34. Grabovsky Y and Tallarida RJ. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther 2004; 310: 981-986.
35. Tallarida RJ. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 2006; 319: 1-7.
36. Tallarida RJ. Interactions between drugs and occupied receptors. Pharmacol Ther 2007; 113: 197-209.
37. Tallarida RJ. Drug synergism and dose-effect data analysis. CRC Press; 2000.
38. Stathopoulos GP. Cisplatin: process and future. J BUON 2013; 18: 564-569.
39. Nervi C, De Marinis E and Codacci-Pisanelli G. Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics 2015; 7: 127.
40. Chodurek E, Orchel A, Gruchlik A, Aleksander E, Golabek K and Dzierzewicz Z. Valproic acid enhances cisplatin cytotoxicity in melanoma cells. Acta Pol Pharm 2012; 69: 1298-1302.
41. Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD and Yu MH. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci 2008; 99: 1218-1226.
42. Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, Jonas D, Doerr HW and Cinatl J Jr. Valproic acid inhibits adhe-sion of vincristine-and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer 2007; 96: 1699-1706.
43. Ong PS, Wang XQ, Lin HS, Chan SY and Ho PC. Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells. Int J Oncol 2012; 40: 1705-1713.
44. Suzuki M, Endo M, Shinohara F, Echigo S and Rikiishi H. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 2009; 64: 1115-1122.
45. Teuschler L, Klaunig J, Carney E, Chambers J, Conolly R, Gennings C, Giesy J, Hertzberg R, Klaassen C and Kodell R. Support of science-based decisions concerning the evaluation of the toxicology of mixtures: a new beginning. Regul Toxicol Pharmacol 2002; 36: 34-39.
46. Greco WR, Bravo G and Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47: 331-385.
47. Jagdev S, Coleman R, Shipman C, Rostami-H A and Croucher P. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126.
48. Noureen N, Rashid H and Kalsoom S. Identification of type-specific anticancer histone dea-cetylase inhibitors: road to success. Cancer Chemother Pharmacol 2010; 66: 625-633.
49. Botrugno OA, Santoro F and Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 2009; 280: 134-144.
50. Zhang X, Jiang SJ, Shang B and Jiang HJ. Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line. Thorac Cancer 2015; 6: 202-208.
51. https://clinicaltrials.gov/ct2/results?term=histone+deacetylase+inhibitors++and+CDDP&pg=1.
52. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR and Belani CP. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 56-62.
53. Han JY, Lee SH, Lee GK, Yun T, Lee YJ, Hwang KH, Kim JY and Kim HT. Phase I/II study of gefitinib (Iressa(R)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2015; 75: 475-483.